Observational analysis evaluated efficacy and adverse reaction rates in AML, suggesting that venetoclax may enhance chemotherapy outcomes through machine learning prognostic models.
Key Points
High response rates achieved with venetoclax-enhanced intensive chemotherapy in Fit AML patients.
Machine learning algorithms including Random Forest and Logistic Regression were used for prognostic modeling.
Analysis identified risk stratification factors like CD4+/CD8+ T-cell ratio and adverse reaction rates.
Clinical utility validated through risk stratification for personalized treatment guidance in AML cases.